Tae Woo Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tae Woo Kim has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hyeongseop Keum
Harvard Medical School Boston Massachusetts USA
2 shared publications - Sangyong Jon
Department of Biological Sciences KAIST Institute for the BioCentury Korea Advanced Institute of Science and Technology (KAIST) Daejeon Republic of Korea
2 shared publications - Wonsik Jung
Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea; Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea
2 shared publications - Chang-Hee Whang
Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea; Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea
1 shared publication - Dohyeon Kim
Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
1 shared publication Dong Eon Kim
School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon 34141, Republic of Korea
1 shared publication
Latest Publications
- 1 August 2021
- Published by Elsevier in Biomaterials
- Vol. 275, 120986
A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis
- 1 August 2021
- Published by Elsevier in Biomaterials
- Vol. 275, 120986
A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis
- 1 March 2021
- Published by Elsevier in Journal of Controlled Release
- Vol. 331, 74-84
Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells
- 1 March 2021
- Published by Elsevier in Journal of Controlled Release
- Vol. 331, 74-84
Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells